Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 0.44 |
| ▸ | RAB9A | P51151 | 10/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4365495 | 0.91 | NPC1 (0.45) | NPC1RAB9ASMN1; SMN2LMNAKMT2A | |
| SCHEMBL4368858 | 0.83 | MEN1 (0.50) | NPC1RAB9ASMN1; SMN2LMNAKMT2A | |
| SCHEMBL6092966 | 0.76 | SMN1; SMN2 (0.45) | SMN1; SMN2LMNAKMT2AMEN1POLB | |
| SCHEMBL6092660 | 0.72 | SMN1; SMN2 (0.43) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4367689 | 0.72 | HPGD (0.49) | NPC1RAB9ASMN1; SMN2LMNAKMT2A | |
| SCHEMBL4372973 | 0.71 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2LMNAKMT2A | |
| SCHEMBL6094816 | 0.70 | LMNA (0.54) | NPC1RAB9ASMN1; SMN2LMNAKMT2A | |
| SCHEMBL6091957 | 0.70 | LMNA (0.54) | NPC1RAB9ASMN1; SMN2LMNAKMT2A | |
| SCHEMBL6092695 | 0.69 | PDE10A (0.44) | NPC1RAB9ASMN1; SMN2LMNAKMT2A | |
| SCHEMBL4363669 | 0.69 | FFAR2 (0.56) | NPC1RAB9ASMN1; SMN2LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060036098-A1 | Carbonylamino-benzimidazole derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2006-02-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060036098-A1 | Carbonylamino-benzimidazole derivatives as androgen receptor modulators | AR, SHBG, BRCA1 | NPC1 3580/4885RAB9A 4310/4885SMN1; SMN2 2413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.